Top

Published in:

01-11-2019 | Original Article

Contribution of Fcγ receptor IIB to creating a suppressive tumor microenvironment in a mouse model

Authors: Yuki Kasahara, Hidekazu Shirota, Sho Umegaki, Chikashi Ishioka

Published in: Cancer Immunology, Immunotherapy | Issue 11/2019

Abstract

Various immune cells are recruited in the tumor microenvironment. It is well established that cellular immune responses, such as cytotoxic or suppressive activities, play an important role in regulating tumor growth and metastasis. However, the contribution of humoral immune responses against tumors is poorly understood. Fc receptors constitute critical elements for the up- or downregulation of immune responses through immune complexes. Here, we examined the potential role of the inhibitory Fc receptor, Fcγ receptor IIB (FcγRIIB), in tumor immunity using a mouse model. Our findings indicated that tumor-specific antibodies are induced in tumor-bearing mice and control tumor immunity. FcγRIIB deletion significantly improved both cellular and humoral immunity against tumors and delayed tumor growth. These findings indicated that spontaneous antibodies against tumors create a suppressive tumor microenvironment through FcγRIIB signaling, thus suggesting an attractive therapeutic target for cancer immunotherapy.

Available only for authorised users

Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014–1022CrossRefPubMedPubMedCentral

Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715–727CrossRefPubMed

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science (New York, N.Y.) 331:1565–1570CrossRef

van Kempen LC, Ruiter DJ, van Muijen GN, Coussens LM (2003) The tumor microenvironment: a critical determinant of neoplastic evolution. Eur J Cell Biol 82:539–548CrossRefPubMed

Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science (New York, N.Y.) 348:74–80CrossRef

Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H, Blankenstein T (2003) A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 63:4095–4100PubMed

Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–1437CrossRefPubMedPubMedCentral

Nimmerjahn F, Ravetch JV (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8:34–47CrossRefPubMed

Pincetic A, Bournazos S, DiLillo DJ, Maamary J, Wang TT, Dahan R, Fiebiger BM, Ravetch JV (2014) Type I and type II Fc receptors regulate innate and adaptive immunity. Nat Immunol 15:707–716CrossRefPubMedPubMedCentral

10.

DiLillo DJ, Ravetch JV (2015) Fc-receptor interactions regulate both cytotoxic and immunomodulatory therapeutic antibody effector functions. Cancer Immunol Res 3:704–713CrossRefPubMed

11.

Bournazos S, Wang TT, Dahan R, Maamary J, Ravetch JV (2017) Signaling by antibodies: recent progress. Annu Rev Immunol 35:285–311CrossRefPubMedPubMedCentral

12.

Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24:19–28CrossRefPubMed

13.

Bolland S, Yim YS, Tus K, Wakeland EK, Ravetch JV (2002) Genetic modifiers of systemic lupus erythematosus in Fc gamma RIIB(−/−) mice. J Exp Med 195:1167–1174CrossRefPubMedPubMedCentral

14.

Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV (1999) Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 189:179–185CrossRefPubMedPubMedCentral

15.

Jiang Y, Hirose S, Abe M, Sanokawa-Akakura R, Ohtsuji M, Mi X, Li N, Xiu Y, Zhang D, Shirai J, Hamano Y, Fujii H, Shirai T (2000) Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics 51:429–435CrossRefPubMed

16.

McGaha TL, Karlsson MC, Ravetch JV (2008) FcgammaRIIB deficiency leads to autoimmunity and a defective response to apoptosis in Mrl–MpJ mice. J Immunol 180:5670–5679CrossRefPubMed

17.

Takai T, Ono M, Hikida M, Ohmori H, Ravetch JV (1996) Augmented humoral and anaphylactic responses in Fc gamma RII-deficient mice. Nature 379:346–349CrossRefPubMed

18.

Yuasa T, Kubo S, Yoshino T, Ujike A, Matsumura K, Ono M, Ravetch JV, Takai T (1999) Deletion of fc gamma receptor IIB renders H-2(b) mice susceptible to collagen-induced arthritis. J Exp Med 189:187–194CrossRefPubMedPubMedCentral

19.

Kobayashi N, Hong C, Klinman DM, Shirota H (2013) Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2. J Immunol 190:1882–1889CrossRefPubMed

20.

Shirota Y, Shirota H, Klinman DM (2012) Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 188:1592–1599CrossRefPubMed

21.

Ito SE, Shirota H, Kasahara Y, Saijo K, Ishioka C (2017) IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. Cancer Immunol Immunother CII 66:1485–1496CrossRefPubMed

22.

Warren MK, Vogel SN (1985) Bone marrow-derived macrophages: development and regulation of differentiation markers by colony-stimulating factor and interferons. J Immunol 134:982–989PubMed

23.

Benvenuto M, Mattera R, Masuelli L, Tresoldi I, Giganti MG, Frajese GV, Manzari V, Modesti A, Bei R (2017) The crossroads between cancer immunity and autoimmunity: antibodies to self antigens. Front Biosci (Landmark Ed) 22:1289–1329CrossRef

24.

Reuschenbach M, von Knebel Doeberitz M, Wentzensen N (2009) A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother CII 58:1535–1544CrossRefPubMed

25.

Zaenker P, Gray ES, Ziman MR (2016) Autoantibody production in cancer-the humoral immune response toward autologous antigens in cancer patients. Autoimmun Rev 15:477–483CrossRefPubMed

26.

Shirota H, Klinman DM, Ito SE, Ito H, Kubo M, Ishioka C (2017) IL4 from T follicular helper cells downregulates antitumor immunity. Cancer Immunol Res 5:61–71CrossRefPubMed

27.

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, Mehta NK, Kauke MJ, Suh H, Cochran JR, Lauffenburger DA, Wittrup KD, Irvine DJ (2016) Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med 22:1402–1410CrossRefPubMedPubMedCentral

28.

Pearce OM, Laubli H, Verhagen A, Secrest P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A (2014) Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. Proc Natl Acad Sci USA 111:5998–6003CrossRefPubMedPubMedCentral

29.

Gul N, van Egmond M (2015) Antibody-dependent phagocytosis of tumor cells by macrophages: a potent effector mechanism of monoclonal antibody therapy of cancer. Cancer Res 75:5008–5013CrossRefPubMed

30.

Dahan R, Sega E, Engelhardt J, Selby M, Korman AJ, Ravetch JV (2015) FcgammaRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis. Cancer Cell 28:285–295CrossRefPubMed

31.

Roghanian A, Teige I, Martensson L, Cox KL, Kovacek M, Ljungars A, Mattson J, Sundberg A, Vaughan AT, Shah V, Smyth NR, Sheth B, Chan HT, Li ZC, Williams EL, Manfredi G, Oldham RJ, Mockridge CI, James SA, Dahal LN, Hussain K, Nilsson B, Verbeek JS, Juliusson G, Hansson M, Jerkeman M, Johnson PW, Davies A, Beers SA, Glennie MJ, Frendeus B, Cragg MS (2015) Antagonistic human FcgammaRIIB (CD32B) antibodies have anti-tumor activity and overcome resistance to antibody therapy in vivo. Cancer Cell 27:473–488CrossRefPubMed

32.

Takai T (2002) Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2:580–592CrossRefPubMed

33.

van Montfoort N, t Hoen PA, Mangsbo SM, Camps MG, Boross P, Melief CJ, Ossendorp F, Verbeek JS (2012) Fcgamma receptor IIB strongly regulates Fc gamma receptor-facilitated T cell activation by dendritic cells. J Immunol 189:92–101CrossRefPubMed

34.

Muller AJ, Scherle PA (2006) Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 6:613–625CrossRefPubMed

35.

Wei SC, Duffy CR, Allison JP (2018) Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 8:1069–1086CrossRefPubMed

36.

Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ (2013) Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization. J Immunol 19:4130–4140CrossRef

37.

Daeron M, Latour S, Malbec O, Espinosa E, Pina P, Pasmans S, Fridman WH (1995) The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc gamma RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation. Immunity 3:635–646CrossRefPubMed

38.

Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (New York, N.Y.) 310:1510–1512CrossRef

Title: Contribution of Fcγ receptor IIB to creating a suppressive tumor microenvironment in a mouse model
Authors: Yuki Kasahara
Hidekazu Shirota
Sho Umegaki
Chikashi Ishioka
Publication date: 01-11-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 11/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02413-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2019

Schwann cells shape the neuro-immune environs and control cancer progression

The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma

Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation

Adhering to adhesion: assessing integrin conformation to monitor T cells

CD4+ T cells indirectly kill tumor cells via induction of cytotoxic macrophages in mouse models

Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer